All News
#EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
Olga Petryna DrPetryna ( View Tweet)
How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA:
-erosion in >=2 consecutive slices or in >=3 SIJ quadrants
- fat lesions w/depth >1cm in >=1SIJ quadrant
are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0192 UK Biobank and IMPALA studies: metabolic body composition of PsA pts w/increased VAT,ectopic liver fat distribution & ⬆️ abdominal fat index associated w/increased risk of CHD&T2DM @RheumNow https://t.co/CwwAB2yUid
Olga Petryna DrPetryna ( View Tweet)
How often do you use MRI of peripheral joints for diagnosis or monitoring of PsA?
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration. @RheumNow https://t.co/ZJBDnZuYbB
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow
Olga Petryna DrPetryna ( View Tweet)
New genome wide association study on anterior uveitis. Heritability for uveitis is 0.7, much greater than axSpA. Includes great data on genetic risk scores @ARVOiovs @AberdeenEpi @hteraG_senoJ https://t.co/gsX39YfrbN https://t.co/e8qBpL5xwy
Dr Philip Robinson philipcrobinson ( View Tweet)
So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA
Janet Pope Janetbirdope ( View Tweet)
ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority. Drop out of TNFi in SpA mirrors RA & PsA @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/dLS2fw5uRP
Janet Pope Janetbirdope ( View Tweet)
Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQ https://t.co/BwU6RF5Qkn
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals. Abstract #AB0660 #EULAR2020 @RheumNow https://t.co/KCMDyzHaSr https://t.co/yFSTgWqzBQ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxs https://t.co/d1RT3GzB2b
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2020 #op0225 sub study of OPAL Balance: withdrawal of MTxdoes not negatively impact Tofa efficacy in PsA. At 6 mo deltaPASDAS 0.229 (0.079) for tofa mono & 0.q138 (0.081) for tofa+mtx. LFT elevation more common in combination arm @RheumNow https://t.co/NO1agViScD
Olga Petryna DrPetryna ( View Tweet)
Majority are correct. 1/3 of SAPHO meet PsA criteria esp if no osteitis @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/B9wp8JxWpI
Janet Pope Janetbirdope ( View Tweet)
